Revenue
2018
2019
2020
2021
2022
2023
2024
Synbiotic SE (SBX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue | €14.3M | €3.9M | €8.2M | €8.7M | €5.5M | €0 | €0 |
| Gross profit | €4.9M | €1.5M | €3.6M | €4.8M | €3.7M | €0 | €0 |
| Gross margin | 34.03% | 39.12% | 43.70% | 55.38% | 68.07% | N/A | N/A |
| Operating expenses | €15.5M | €13.3M | €29.5M | €16.3M | €4.5M | €10,000 | €0 |
| Operating income | −€10.6M | −€11.8M | −€25.9M | −€11.5M | −€830,000 | −€10,000 | €0 |
| Operating margin | −74.00% | −304.40% | −317.26% | −132.83% | −15.23% | N/A | N/A |
| EBITDA | −€2.0M | −€7.1M | −€7.5M | −€5.0M | N/A | N/A | N/A |
| EBITDA margin | −14.16% | −184.52% | −91.62% | −57.77% | N/A | N/A | N/A |
| Net income | −€10.9M | −€11.7M | −€26.0M | −€13.1M | −€880,000 | −€10,000 | €0 |
| Net profit margin | −76.10% | −304.15% | −318.24% | −151.10% | −16.15% | N/A | N/A |
| Basic EPSper basic share | -€1.43 | -€2.12 | -€24.36 | -€3.46 | -€0.34 | -€0.05 | €0.00 |
| Diluted EPSper diluted share | -€1.66 | -€2.24 | -€5.97 | -€4.15 | -€0.56 | -€0.05 | €0.00 |
Owners
Reported ownership